Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis
- PMID: 14723609
- DOI: 10.1111/j.0269-2813.2004.01827.x
Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis
Abstract
Aim: To determine whether there is a difference in short-term adverse events in patients with ulcerative colitis treated with mesalazine, olsalazine or balsalazide.
Methods: MEDLINE was searched for articles published until 2002. Randomized trials of oral mesalazine, olsalazine or balsalazide for the treatment of active disease or the maintenance of remission were included. Outcomes of interest were the frequencies of patients experiencing adverse events and those withdrawn due to adverse events.
Results: Forty-six trials were included. One study of mesalazine vs. sulfasalazine for active colitis showed significantly fewer patients with adverse events with mesalazine. Both balsalazide vs. sulfasalazine studies for active disease showed significantly fewer withdrawals with balsalazide. One trial of balsalazide vs. sulfasalazine for maintenance showed significantly fewer patients with adverse events with balsalazide. Otherwise, no significant differences in safety outcomes were noted.
Conclusion: All three 5-aminosalicylic acid agents are safe in the short term. In mesalazine-treated patients, the frequencies of adverse events or withdrawals due to adverse events were comparable with those in placebo-treated patients and lower than those in sulfasalazine-treated patients. Overall, adverse events or withdrawals were not significantly more frequent with olsalazine than with placebo or sulfasalazine. Adverse events and study withdrawals on balsalazide were less frequent than those on sulfasalazine.
Similar articles
-
A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.Aliment Pharmacol Ther. 2002 Jan;16(1):69-77. doi: 10.1046/j.1365-2036.2002.01151.x. Aliment Pharmacol Ther. 2002. PMID: 11856080 Clinical Trial.
-
Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.Gut. 2001 Dec;49(6):783-9. doi: 10.1136/gut.49.6.783. Gut. 2001. PMID: 11709512 Free PMC article. Clinical Trial.
-
A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.Dig Dis Sci. 2009 Jun;54(6):1157-70. doi: 10.1007/s10620-008-0481-x. Epub 2008 Sep 4. Dig Dis Sci. 2009. PMID: 18770034 Review.
-
Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.Scand J Gastroenterol Suppl. 2002;(236):42-7. doi: 10.1080/003655202320621445. Scand J Gastroenterol Suppl. 2002. PMID: 12408503 Review.
-
Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.Aliment Pharmacol Ther. 1998 Dec;12(12):1207-16. doi: 10.1046/j.1365-2036.1998.00427.x. Aliment Pharmacol Ther. 1998. PMID: 9882028 Clinical Trial.
Cited by
-
Five-aminosalicylic Acid: an update for the reappraisal of an old drug.Gastroenterol Res Pract. 2015;2015:456895. doi: 10.1155/2015/456895. Epub 2015 Jan 21. Gastroenterol Res Pract. 2015. PMID: 25685145 Free PMC article. Review.
-
Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study.Inflamm Bowel Dis. 2015 Jun;21(6):1348-58. doi: 10.1097/MIB.0000000000000368. Inflamm Bowel Dis. 2015. PMID: 25806845 Free PMC article.
-
5-Aminosalicylic acid for treatment of irritable bowel syndrome: A protocol for a systematic review and meta-analysis.Medicine (Baltimore). 2020 Feb;99(9):e19351. doi: 10.1097/MD.0000000000019351. Medicine (Baltimore). 2020. PMID: 32118774 Free PMC article.
-
Is mesalamine safe?Gastroenterol Hepatol (N Y). 2007 Nov;3(11):878-9. Gastroenterol Hepatol (N Y). 2007. PMID: 21960801 Free PMC article. No abstract available.
-
Classical and recent advances in the treatment of inflammatory bowel diseases.Braz J Med Biol Res. 2015 Feb;48(2):96-107. doi: 10.1590/1414-431X20143774. Epub 2014 Nov 28. Braz J Med Biol Res. 2015. PMID: 25466162 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical